Primary Myeloid Sarcoma Masquerading as an Obstructing Duodenal Carcinoma

Table 1

Published reports of primary duodenal myeloid sarcomas (1998–2010).

Case report	Sex, age	Site	Associated malignancy	Karyotype/; cytogenetics	Treatment	Prognosis
Kim 1998 [6]	Male, 57	Duodenum	De novo	NR	Daunorubicin + Cytosine Arabinoside	Remission 7 months with no leukemia
Goor et al.,; 2003 [7]	Male, 27	Duodenum	NR, 30% blasts	Inv (16)	Induction (Cytarabine + Idarubicin), consolidation (high dose Cytarabine), allo BMT	Remission 2 years
Choi et al.,; 2007 [2]	Male, 71	Duodenum	CML	NR	NR	NR
Derenzini et al., 2008 [8]	Male, 40	Stomach (fundus, body), duodenum	De novo, AML 20 days later	45, XY	Induction (Ara-C, Etoposide, Idarubicin, 2nd induction (Ara-C, Idarubicin) after clinical relapse, allo BMT	Expired 50 days post BMT
Ghafoor et al.,; 2010 [9]	Male, 17	Duodenum	AML-M1	NR	2 courses induction (Ara-C, Daunorubicin, Etoposide), consolidation MACE (Amsacrine, Cytosine, Etoposide), + MIDAC (Mitoxantrone, high dose Cytarabine)	In remission 25 months post treatment
Jeong et al.,; 2010 [10]	Male, 35	Duodenum jejunum, left sternocleid-omastoid	AML	46, XY	Induction (Mitoxantrone, Etoposide, Cytarabine)	Expired due sepsis after chemotherapy
Antic et al.,; 2010 [11]	Female, 28	Duodenum	Primary, AML 2 months later	46, XX	Patient refused treatment	NR

NR: not reported; BMT: bone marrow transplant.